Drug that targets cancer in a radically different way approved in U.S.

Drug that targets cancer in a radically different way approved in U.S.

PanARMENIAN.Net - The US Food and Drug Administration has approved a drug for a wide range of cancers based on a shared mutation, rather than the tumors' locations - an advance for the sometimes controversial field of "precision medicine", Sceince Alert reports.

The medication, called Vitrakvi, is the second treatment to receive FDA clearance based on a common biomarker found in an array of cancers. The drug, also called larotrectinib, was approved simultaneously for adults and children.

Typically, oncology drugs are considered much later for children.

Last year the agency, for the first time, approved an immunotherapy drug for tumors with a specific genetic signature, regardless of where they originated in the body. But that treatment had been cleared for several cancers, including advanced melanoma.

The drug is for patients with advanced solid tumors containing what's called an NTRK gene fusion, a hybrid of two genes that can promote uncontrolled cell growth.

Cancers of the thyroid, lung, and head and neck, among others, can be caused by the defect.

The drug is for patients whose cancer has spread or who would experience severe complications by undergoing surgery and have no satisfactory alternatives.

 Top stories
The company got its first break with a contract to build code-making machines for U.S. troops during World War II.
The study new found that ocean temperatures in the last decade have been the warmest on record.
The deal will involve the duchess doing a voiceover in return for a donation to Elephants Without Borders.
The story by Chris McCormick follows two cousins in Soviet Armenia who consider themselves brothers.
Partner news